VIIV HEALTHCARE PTY LTD

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Maraviroc
Drug: Maraviroc + Boceprevir
Drug: Maraviroc + Telaprevir

First Posted Date: 2012-05-14

Last Posted Date: 2012-09-19

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 14

Registration Number: NCT01597895

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: GSK1265744 LAP 800mg intramuscular injection
Drug: GSK1265744 Oral
Drug: GSK1265744 LAP 200mg intramuscular injection
Drug: GSK1265744 LAP 400mg intramuscular injection
Drug: GSK1265744 LAP 200mg subcutaneous injection
Drug: TMC278 LA 1200mg intramuscular injection
Drug: TMC278 LA 600mg intramuscular injection

First Posted Date: 2012-05-07

Last Posted Date: 2014-02-10

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 43

Registration Number: NCT01593046

Locations: 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States

Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Dolutegravir 50 mg twice daily
Drug: Dolutegravir placebo twice daily

First Posted Date: 2012-04-02

Last Posted Date: 2018-07-02

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 30

Registration Number: NCT01568892

Locations: 🇺🇸
GSK Investigational Site, Annandale, Virginia, United States

A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: DTG
Drug: BCV
Drug: TVR

First Posted Date: 2012-03-26

Last Posted Date: 2017-03-28

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 32

Registration Number: NCT01563328

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

Dolutegravir Expanded Access Study

Not Applicable

Completed

Conditions: Infection, Human Immunodeficiency Virus
HIV Infections

First Posted Date: 2012-02-22

Last Posted Date: 2020-09-30

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 200

Registration Number: NCT01536873

Locations: 🇵🇱
GSK Investigational Site, Szczecin, Poland

Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: Ortho-Cyclen
Drug: Dolutegravir
Drug: Placebo

First Posted Date: 2011-12-26

Last Posted Date: 2012-05-21

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 16

Registration Number: NCT01498861

Locations: 🇺🇸
GSK Investigational Site, Miami, Florida, United States

A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects

Phase 3

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: Dolutegravir

First Posted Date: 2011-12-26

Last Posted Date: 2015-02-25

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 13

Registration Number: NCT01499199

Locations: 🇺🇸
GSK Investigational Site, Providence, Rhode Island, United States

A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects

Phase 1

Completed

Conditions: Infections, Human Immunodeficiency Virus and Hepatitis

Interventions: Drug: Dolutegravir
Drug: Rlipivirine
Drug: GSK1265744

First Posted Date: 2011-11-08

Last Posted Date: 2012-10-15

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 28

Registration Number: NCT01467531

Locations: 🇺🇸
GSK Investigational Site, Buffalo, New York, United States

Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.

Phase 1

Completed

Conditions: Infections, Human Immunodeficiency Virus and Hepatitis

Interventions: Drug: Methadone
Drug: Dolutegravir

First Posted Date: 2011-11-08

Last Posted Date: 2012-04-09

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 11

Registration Number: NCT01467518

Locations: 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada

Drug Exposure Registry for GSK2248761, an Investigational NNRTI

Completed

Conditions: HIV Infections

First Posted Date: 2011-10-24

Last Posted Date: 2019-09-11

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 19

Registration Number: NCT01458132

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy